April W Armstrong
Overview
Explore the profile of April W Armstrong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
448
Citations
8268
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zhang A, Ball G, Zundell M, Aguero R, Yee D, Shields A, et al.
J Drugs Dermatol
. 2024 Dec;
23(12):1114-1120.
PMID: 39630678
Background: International Dermatology Outcome Measures (IDEOM) is a non-profit organization whose mission is to improve the availability of evidence-based, consensus-driven outcome measures for dermatological diseases. IDEOM facilitates collaboration between stakeholders...
12.
Armstrong A, Bissonnette R, Chovatiya R, Bhutani T, Brown P, Tallman A, et al.
Cutis
. 2024 Dec;
114(4):122-127.
PMID: 39621574
The National Psoriasis Foundation (NPF) treatment targets aim to achieve 1% or lower body surface area (BSA) affected after 3 months of treatment. European psoriasis treatment guidelines aim to achieve...
13.
Sadrolashrafi K, Hao A, Yamamoto R, Guo L, Kikuchi R, Tolson H, et al.
BMC Health Serv Res
. 2024 Nov;
24(1):1504.
PMID: 39614287
Background: Psoriasis is a chronic, inflammatory skin condition requiring long-term care. However, many psoriasis patients may not regularly receive care. Several factors affect access to care in the United States,...
14.
Armstrong A, Lebwohl M, Warren R, Sofen H, Imafuku S, Ohtsuki M, et al.
JAMA Dermatol
. 2024 Nov;
161(1):56-66.
PMID: 39602111
Importance: Safe and effective long-term treatments for moderate to severe plaque psoriasis are needed. Objective: To evaluate the long-term safety and efficacy of deucravacitinib through 3 years (week 148) in...
15.
Lebwohl M, Koo J, Armstrong A, Strober B, Yoon S, Rawnsley N, et al.
Dermatol Ther (Heidelb)
. 2024 Nov;
15(1):213-222.
PMID: 39589679
Introduction: Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have...
16.
Simpson E, Augustin M, Thaci D, Misery L, Armstrong A, Blauvelt A, et al.
Am J Clin Dermatol
. 2024 Nov;
26(1):121-137.
PMID: 39546129
Background: Atopic dermatitis (AD) is associated with itch, skin pain, sleep disturbances, and diminished quality of life (QoL). Ruxolitinib (Janus kinase [JAK] 1/JAK2 inhibitor) cream demonstrated efficacy and safety in...
17.
Tsai T, Tada Y, Kung C, Zhong Y, Cichewicz A, Borkowska K, et al.
J Dermatol
. 2024 Nov;
51(12):1559-1571.
PMID: 39526612
Expanding the systemic treatment options for patients with psoriasis, deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor is approved in the United States, European Union, China, Japan, Taiwan, Korea,...
18.
Guo L, Bilimoria S, Kikuchi R, Hao A, Sadrolashrafi K, Yamamoto R, et al.
J Invest Dermatol
. 2024 Nov;
PMID: 39522941
No abstract available.
19.
Korouri E, Jeong C, Peterson H, Valenzuela F, Romiti R, Didaskalu J, et al.
Life (Basel)
. 2024 Oct;
14(10).
PMID: 39459597
(1) Background: The purpose of this study is to compare the rate of COVID-19 vaccination among psoriasis patients internationally and to correlate it with their treatment regimens. (2) Methods: We...
20.
Armstrong A, Soliman A, Gisondi P, Fang S, Patel M, Strober B
Dermatol Ther (Heidelb)
. 2024 Oct;
14(11):3071-3081.
PMID: 39453596
Introduction: Despite advancements in the treatment of psoriasis (PsO), there are few head-to-head studies assessing comparative effectiveness of the newest therapies approved to treat PsO. Our objective was to assess...